Skip to content

Top gainers Top losers Most active Market sectors Heatmap Treasury rates

Earnings calendar IPO calendar Ex-dividend calendar Economic calendar

Congress trades Insider trades Analyst upgrades & downgrades

Screener Compare Backtester

Valuation Fundamentals

Watchlist Portfolio

⌕/

Markets

Stocks Gainers Losers Most active Market sectors Heatmap Earnings calendar Congress trades Insider trades Analyst upgrades/downgrades IPO calendar Ex-dividend calendar

Tools

Screener Compare stocks Returns backtester Portfolio tracker Watchlist Embeddable widget

Metrics

Valuation Fundamentals

Popular lists

Best dividend stocks Best value stocks Largest companies Lowest P/E stocks

Collections

All lists & collections US stocks Japanese stocks Chinese stocks Hong Kong stocks South Korean stocks Taiwanese stocks Canadian stocks UK stocks European stocks Magnificent 7 AI stocks Semiconductor stocks

Compare

Compare stocks Finviz alternative Koyfin alternative TradingView alternative StockAnalysis alternative

Learn

Investing glossary Help & guide

StockMarketCapDocs Token Terms PrivacyData for information only, not investment advice.

◆

Enliven Therapeutics, Inc. (ELVN) News - StockMarketCap

Stocks›Enliven Therapeutics, Inc.☆

● At closeAs of Jul 2, 2026

Enliven Therapeutics, Inc.

ELVN✓

HealthcareBiotechnologyNASDAQ

$49.82+2.17%

$3.56BMarket cap

-P/E ratio

844.24KVolume (24h)

Overview Forecast Valuation Financials Technical Dividends Smart money News

Price

$49.82

$1.06 (+2.17%) · 24h

Key metrics

Market cap$3.56B+35.30%

Enterprise value$3.56B

Volume (24h)844.24K

P/E ratio (TTM)-

P/S ratio (TTM)-

Dividend yield-

Shares outstanding71.44M

Trading range

Previous close$48.76

Day range$47.45 - $50.21

52-week range-

Enliven Therapeutics, Inc. (ELVN) operates in the Biotechnology industry within the Healthcare sector, listed on NASDAQ.

Similar stocks

Eli Lilly and Company+1.57%

Johnson & Johnson+3.57%

AbbVie Inc.+3.99%

UnitedHealth Group Incorporated-0.28%

Roche Holding AG+3.89%

Merck & Co., Inc.+3.31%

Latest news